Nova Biomedical Enhances Biopharma Workflow with NanoCellect Acquisition

Nova Biomedical's Strategic Acquisition of NanoCellect

In a significant move to enhance its capabilities, Nova Biomedical has announced the acquisition of specific assets from NanoCellect, a company renowned for its innovative microfluidic cell sorting technology. This acquisition marks a vital step in expanding Nova Biomedical’s portfolio, particularly in the realm of cell line development, and positions the company to better support biopharmaceutical workflows spanning from early development stages to manufacturing.

The integration of NanoCellect’s flagship product, the WOLF G2 cell sorting platform, represents a substantial upgrade for Nova Biomedical’s offerings. This technology boasts a gentle, microfluidic-based approach to cell selection and isolation, which complements Nova's existing Solentim products tailored for clone generation, verification, and growth analysis. By merging these powerful technologies, Nova Biomedical aims to create a more cohesive strategy for cell line development—streamlining the processes of cell selection, single-cell isolation, and clone verification to ensure high-confidence results.

As the biopharmaceutical industry becomes increasingly competitive, the demand for faster and more effective cell line development processes continues to grow. The expansion of Nova's portfolio is expected to significantly accelerate development timelines for cell lines and enhance the outcomes of clone selection. This integration also aims to fortify the groundwork necessary for process development, scale-up, and eventual manufacturing within various biopharmaceutical sectors.

Moreover, Nova Biomedical is recognized for its analytical solutions designed for meticulous cell culture monitoring. Key products in its arsenal include the BioProfile® FLEX2 for metabolite analysis, OsmoTECH® for osmolality measurements, and BioProfile® FAST CDV for reliable cell counting and viability assessments. These tools play a critical role in maintaining quality control throughout the bioprocessing workflow, serving customers from the development phase through to full production.

The acquisition of NanoCellect’s products is a strategic effort by Nova Biomedical to provide a more interconnected portfolio of technologies. This integration supports continuity and insight across the entire bioprocessing lifecycle, ensuring that clients are equipped with the necessary tools to make informed decisions while optimizing their workflows.

John Luck, President of Nova Biomedical's Biopharma Business, expressed enthusiasm regarding the acquisition, stating, "NanoCellect adds a critical upstream capability to our portfolio and strengthens our ability to connect key steps in cell line development. By integrating cell sorting with clone isolation and high-confidence verification, we enable our customers to achieve successful clones more quickly while generating insights that optimize clone selection and enhance process development, scale-up, and manufacturing performance. This integration marks an important milestone in building a more connected and differentiated platform for cell line development and bioprocessing."

About Nova Biomedical

Founded on innovation, Nova Biomedical is a global leader in providing advanced analytical instruments tailored for the biopharmaceutical and clinical markets. Its extensive portfolio supports essential workflows across cell line development, process development, and manufacturing, ultimately enabling customers to achieve improved productivity, quality, and operational efficiency.

About NanoCellect

NanoCellect specializes in developing microfluidic cell sorting technologies, focusing on gentle and sterile cell isolation solutions. Its platforms are widely utilized in applications such as cell line development, single-cell analysis, and cell therapy research, positioning the company as a significant player in the cell biology market.

As Nova Biomedical continues to advance its technologies through strategic acquisitions and integrations, it remains committed to empowering researchers and manufacturers with cutting-edge solutions for biopharmaceutical development. As this field evolves, such advancements will be critical in driving innovation and maintaining competitive advantages in the ever-demanding landscape of biopharmaceutical research and production.